Edwards Lifesciences (NYSE: EW) and Edap Tms (NASDAQ:EDAP) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.
Risk & Volatility
Edwards Lifesciences has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500. Comparatively, Edap Tms has a beta of 0.72, meaning that its stock price is 28% less volatile than the S&P 500.
This table compares Edwards Lifesciences and Edap Tms’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Edwards Lifesciences||$3.44 billion||8.61||$583.60 million||$3.80||37.08|
|Edap Tms||$40.74 million||1.64||-$770,000.00||($0.01)||-230.00|
Edwards Lifesciences has higher revenue and earnings than Edap Tms. Edap Tms is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
82.9% of Edwards Lifesciences shares are owned by institutional investors. Comparatively, 9.4% of Edap Tms shares are owned by institutional investors. 2.1% of Edwards Lifesciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
This table compares Edwards Lifesciences and Edap Tms’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of current ratings for Edwards Lifesciences and Edap Tms, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Edwards Lifesciences presently has a consensus target price of $145.40, suggesting a potential upside of 3.19%. Edap Tms has a consensus target price of $7.00, suggesting a potential upside of 204.35%. Given Edap Tms’ stronger consensus rating and higher possible upside, analysts plainly believe Edap Tms is more favorable than Edwards Lifesciences.
Edwards Lifesciences beats Edap Tms on 12 of the 15 factors compared between the two stocks.
Edwards Lifesciences Company Profile
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World. Its products are categorized into three areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy and Critical Care. It also develops hemodynamic monitoring systems that are used to measure a patient’s cardiovascular function in the hospital setting. It is developing products, such as the Edwards SAPIEN 3 Ultra System and Edwards SAPIEN XT transcatheter heart valve, among others. Its Transcatheter Heart Valve Therapy and Surgical Heart Valve Therapy products are manufactured in the United States, Singapore and Switzerland. Critical Care products are manufactured in its facilities located in Puerto Rico and the Dominican Republic.
Edap Tms Company Profile
EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases worldwide. The company operates in two divisions: High Intensity Focused Ultrasound (HIFU), and Urology Devices and Services (UDS). The HIFU division develops, manufactures, and markets devices for the minimally invasive destruction of various types of localized tumors using HIFU technology. It offers Ablatherm, a HIFU device for the treatment of organ-confined prostate cancer, referred to as T1-T2 stage; and Focal One device, a HIFU robotic device for the focal therapy of localized prostate cancer. This division also leases equipment; sells disposables and spare parts; and offers maintenance services. The UDS division develops, manufactures, markets, and services medical devices for the minimally invasive diagnosis or treatment of urological disorders primarily urinary stones and other clinical indications. It offers lithotripters, such as Sonolith i-move and Sonolith i-sys for the treatment of urinary tract stones by means of extracorporeal shockwave lithotripsy technology. This division also leases lithotripters; sells disposables and spare parts; and provides maintenance services. The company markets and sells its products through its direct marketing and sales organization, as well as through third-party distributors and agents. Its customers include public and private hospitals, urology clinics, and research institutions. The company was founded in 1979 and is based in Vaulx-en-Velin, France.
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.